

| | Total CHR cohort (n=254) | Total HC cohort (n=116) | p |
|------------------------------------|---|---|------------------|
| Age | 22.70 ± 5.00 (range 14 to 45) | 23.54 ± 3.38 (range 17 to 34) | 0.057 |
| Sex [M: n (%)] | 136 (53.5) | 60 (51.7) | 0.822 |
| Ethnicity [n (%)] | White 178 (70.4), Black 22 (8.7), Other 53 (20.9) | White 76 (65.5), Black 24 (20.7), Other 16 (13.8) | 0.003 |
| Smoker* [n (%)] | 133 (53.4) | 31 (26.7) | <0.001 |
| BMI | 24.31 ± 5.30 | 23.70 ± 4.44 | 0.288 |
| Current antipsychotic use [n (%)] | 24 (9.4) | 0 (0) | <0.001 |
| S100B (ug/L)** | 0.040 ± 0.049 | 0.050 ± 0.071 | 0.833 |
| CRP (mg/L)** | 1.23 ± 1.08 | 0.95 ± 0.95 | 0.048 |
| Any antibody (fixed CBA) [n (%)] | 21 (8.3) | 6 (5.2) | 0.390 |
| IgG [n (%)] | 9 (3.5) | 4 (3.4) | 1.000 |
| IgA [n (%)] | 8 (3.1) | 1 (0.9) | 0.283 |
| IgM [n (%)] | 5 (2.0) | 1 (0.9) | 0.670 |
| NMDAR antibody (fixed CBA) [n (%)] | 11 (4.3) | 2 (1.7) | 0.360 |

| | | | |
|-------------------------------------|----------|---------|-------|
| <i>NMDAR IgG [n (%)]</i> | 1 (0.4) | 1 (0.9) | 0.529 |
| <i>NMDAR IgA [n (%)]</i> | 6 (2.4) | 0 (0.0) | 0.183 |
| <i>NMDAR IgM [n (%)]</i> | 4 (1.6) | 1 (0.9) | 1.000 |
| <i>NMDAR IgG (live CBA) [n (%)]</i> | 13 (5.1) | 6 (5.2) | 1.000 |

Table 1: Demographic/basic clinical information and NSAb serostatus by group

*data available for 365 of 370 subjects

**Adjusted for BMI, gender, age, ethnicity and smoking status

Abbreviations: CHR: clinical high risk, HC: healthy control, CBA: cell-based assay, S100B: S100 calcium-binding protein B, CRP: C-reactive protein, NMDAR: N-methyl-d-aspartate receptor.

| | <i>Any antibody negative (n=343)</i> | <i>Any antibody positive (fixed CBA) (n=27)</i> | <i>p</i> | <i>NMDAR antibody negative (fixed CBA) (n=357)</i> | <i>NMDAR antibody positive (fixed CBA) (n=13)</i> | <i>p</i> | <i>NMDAR antibody negative (live CBA) (n=351)</i> | <i>NMDAR antibody positive (live CBA) (n=19)</i> | <i>p</i> |
|--|---|---|----------|--|---|----------|---|--|----------|
| <i>Age</i> | 23.01 ± 4.60 | 22.33 ± 4.13 | 0.458 | 22.97 ± 4.57 | 22.69 ± 4.57 | 0.829 | 22.92 ± 4.50 | 23.79 ± 5.73 | 0.418 |
| <i>Sex [M: n (%)]</i> | 178 (51.9) | 18 (66.7) | 0.163 | 187 (52.4) | 9 (69.2) | 0.270 | 188 (53.6) | 11 (57.9) | 0.330 |
| <i>Ethnicity [n (%)]</i> | White 231 (67.5) Black 45 (13.2) Other 66 (19.3) | White 23 (85.2) Black 1 (3.7) Other 3 (11.1) | 0.148 | White 44 (68.5) Black 45 (12.6) Other 67 (18.8) | White 10 (76.9) Black 1 (7.7) Other 2 (15.4) | 0.797 | White 243 (69.4) Black 43 (12.3) Other 64 (18.3) | White 11 (57.9) Black 3 (15.8) Other 5 (26.3) | 0.563 |
| <i>Smoker* [n (%)]</i> | 155 (45.9) | 9 (33.3) | 0.233 | 160 (45.5) | 4 (30.8) | 0.398 | 155 (44.8) | 9 (47.4) | 0.826 |
| <i>BMI</i> | 24.17 ± 4.98 | 23.19 ± 5.55 | 0.370 | 24.07 | 24.94 | 0.591 | 24.12 ± 5.02 | 23.82 ± 5.10 | 0.815 |
| <i>Current antipsychotic use [n (%)]</i> | 21 (6.1) | 3 (11.1) | 0.403 | 22 (6.2) | 2 (15.4) | 0.203 | 22 (6.3) | 2 (10.5) | 0.463 |
| <i>CRP (mg/L)**</i> | 1.14 ± 1.04 | 1.12 ± 1.21 | 0.991 | 1.14 ± 1.04 | 1.28 ± 1.41 | 0.925 | 1.14 ± 1.05 | 1.17 ± 0.94 | 0.506 |

| | | | | | | | | | |
|-----------------------|---------------|---------------|-------|---------------|--------------|-------|---------------|---------------|-------|
| <i>S100B</i> (ug/L)** | 0.043 ± 0.058 | 0.038 ± 0.033 | 0.613 | 0.043 ± 0.057 | 0.04 ± 0.043 | 0.994 | 0.043 ± 0.058 | 0.037 ± 0.031 | 0.783 |
|-----------------------|---------------|---------------|-------|---------------|--------------|-------|---------------|---------------|-------|

Table 2: Demographic/basic clinical information by NSAb serostatus

*data available for 365 of 370 subjects

**Statistic adjusted for BMI, gender, age, ethnicity and smoking status

Abbreviations: CBA: cell-based assay, S100B: S100 calcium-binding protein B, CRP: C-reactive protein, NMDAR: N-methyl-d-aspartate receptor, BMI: body mass index.

| | <i>Antibody positive</i> | <i>Antibody negative</i> | <i>F (serostatus)</i> | <i>p (serostatus)</i> |
|--|------------------------------|------------------------------|-----------------------|-----------------------|
| <i>NMDAR ANTIBODY (IgG, IgA, IgM; FIXED ASSAY)</i> | | | | |
| <i>AVLT IR total (7:160)</i> | 52.00 ± 13.79 | 63.06 ± 11.90 | 4.817 | 0.030 |
| <i>AVLT IR total (CAARMS adjusted) (5:127)</i> | 45.80 ± 10.69 | 62.50 ± 11.90 | 7.651 | 0.007 |
| <i>WAIS estimated total IQ (9:222)</i> | 84.22 ± 20.35 | 98.71 ± 16.90 | 6.687 | 0.010 |
| <i>WAIS estimated total IQ (CAARMS adjusted) (7:182)</i> | 83.29 ± 21.62 | 100.32 ± 16.86 | 7.134 | 0.008 |
| <i>CAARMS total (9:198)</i> | 49.00 ± 16.17 | 49.49 ± 15.00 | 0.001 | 0.981 |
| <i>BPRS positive sx (11:224)</i> | 14.91 ± 5.43 | 13.55 ± 4.54 | 0.731 | 0.393 |
| <i>SANS (9:210)</i> | 20.44 ± 15.30 | 15.53 ± 11.74 | 1.074 | 0.301 |
| <i>YMRS (11:225)</i> | 4.27 ± 5.35 | 4.00 ± 4.79 | 0.03 | 0.957 |
| <i>MADRS (11:230)</i> | 20.91 ± 12.98 | 18.69 ± 9.16 | 0.650 | 0.421 |
| <i>NMDAR ANTIBODY (IgG; LIVE ASSAY)</i> | | | | |

| | | | | |
|--|------------------|-------------------|-------|-------|
| <i>AVLT IR total</i> (9:158) | 58.00 ± 13.90 | 62.86 ± 12.03 | 0.929 | 0.337 |
| <i>AVLT IR total (CAARMS adjusted)</i> (9:123) | 58.00 ± 13.90 | 62.15 ± 12.13 | 0.826 | 0.365 |
| <i>WAIS estimated total IQ</i> (12:219) | 95.00 ± 19.98 | 98.32 ± 17.10 | 0.067 | 0.796 |
| <i>WAIS estimated total IQ (CAARMS adjusted)</i> (12:177) | 95.00 ± 19.98 | 100.01 ± 17.11 | 0.353 | 0.553 |
| <i>CAARMS total</i> (13:194) | 51.00 ± 11.90 | 49.37 ± 15.21 | 0.197 | 0.657 |
| <i>BPRS positive sx</i> (13:222) | 14.62 ± 4.82 | 13.56 ± 4.57 | 0.683 | 0.409 |
| <i>SANS</i> (13:206) | 15.31 ± 11.39 | 15.76 ± 11.96 | 0.058 | 0.810 |
| <i>YMRS</i> (12:224) | 6.50 ± 5.16 | 3.89 ± 4.76 | 3.179 | 0.076 |
| <i>MADRS</i> (13:228) | 23.69 ± 9.05 | 18.51 ± 9.30 | 3.847 | 0.051 |

Table 3: Cognitive function and psychopathology scores by NMDAR antibody serostatus (descriptive means shown with F and p values from ANOVA). Numbers in brackets under variable names are the number of seropositive subjects and seronegative subjects for whom data were available for that variable. BPRS total score excluded from analysis due to heteroscedasticity.

Abbreviations: NMDAR: N-methyl-d-aspartate receptor, AVLT: Rey Auditory Verbal Learning Task, IR: immediate recall, CAARMS: Comprehensive Assessment of At-Risk Mental States, WAIS: Wechsler Adult Intelligence Scale III, BPRS: Brief Psychiatric Rating Scale, SANS: Scale for the Assessment of Negative Symptoms, YMRS: Young Mania Rating Scale, MADRS: Montgomery-Asberg Depression Rating Scale